Abstract: An device edge may receive a machine learning model, and may receive data from an edge device associated with a RAN. The device edge may process the data, with the machine learning model, to generate edge analytic data associated with the edge device, and may process the edge analytic data, with the machine learning model, to detect a problem or to predict an issue associated with the edge device or a RAN device associated with the edge device. The device edge may provide particular edge analytic data associated with the problem or the issue to a cloud-computing system, and may perform one or more actions based on the problem or the issue associated with the edge device or the RAN device.

Abstract: A device may receive edge parameters, geographic data, traffic data, and real-time metadata associated with an approximate location of a mobile edge device and a device edge. The device may receive a request for an actual location of the mobile edge device and the device edge, and may process the edge parameters, the geographic data, the traffic data, and the real-time metadata, with a machine learning model, to calculate multiple locations. The device may discard locations that fail to fit the edge parameters, the geographic data, the traffic data, and the real-time metadata, to generate a set of locations, and may select, from the set of locations, a location with a greatest location confidence determination as the actual location of the mobile edge device and the device edge.

Abstract: A biphasic system and method for assisting breathing of a patient by controllably providing breathing gas to the patient and taking exhaled gas from the patient during inspiration and expiration phases. The system and method having a pair of pressure-controlling means such as hydrostatic pressures or pop-off valves that are coupled to the patient breathing interface. Various means for controlling gas pressure at the breathing interface are described.

Abstract: A novel biphasic pharmaceutial or nutraceutical composition delivers both an immediate and a sustained dose of a pharmaceutical or nutraceutical agent in the same unit dose. An oral unit dose of melatonin includes melatonin in a sustained-release matrix contained in a solid phase, such as a tablet of capsule, and also includes melatonin in a film dispersed on the surface of the solid phase. Approximately 80 to 90 weight percent of the total amount of melatonin of each unit is contained in the sustained-release matrix and the remainder in the film. The novel composition permits a mammal, including a human being, to both rapidly fall asleep and remain asleep for a desired period of time by releasing an immediate-release dose and a sustained-release dose of melatonin.